Inhibitory effects of dobutamine on human gastric adenocarcinoma

Figure 1 Dobutamine inhibits SGC-7901 cell growth. A: Inhibition ratio (%) of dobutamine on the viability of SGC-7901 cells. Cells were treated with different concentrations of dobutamine (1, 3, 10 and 30 μmol/L) for 24, 48 and 72 h; B: Inhibition ratio (%) of dobutamine (30 μmol/L), cisplatin (8 μg/mL) and dobutamine (30 μmol/L) + cisplatin (8 μg/mL) for 24, 48 and 72 h on the viability of SGC-7901 cells. ^aP < 0.05 vs the combined group.

Figure 2 Dobutamine inhibits SGC-7901 cell migration. A: After treatment with 30 μmol/L dobutamine for 24 h, the number of migrated cells was reduced; B: Number of migrated cells was increased in the control group.

Figure 3 Effects of dobutamine on the cell cycle of SGC-7901 cells analyzed by flow cytometry. Cells were treated with different concentrations of dobutamine for 48 h. A: Control cells; B: 1 μmol/L dobutamine; C: 3 μmol/L dobutamine; D: 10 μmol/L dobutamine; E: 30 μmol/L dobutamine.

Figure 4 Effects of dobutamine on apoptosis of SGC-7901 cells. Cells were treated with different concentrations of dobutamine for 72 h. A: Control cells; B: 1 μmol/L dobutamine; C: 3 μmol/L dobutamine; D: 10 μmol/L dobutamine; E: 30 μmol/L dobutamine.

Figure 5 Expression of Yes-associated protein in SGC-7901 cells after treatment with dobutamine for 72 h. A: Yes-associated protein (YAP); B: Phosphorylated YAP; C: GAPHD (control). Immunocytochemistry analysis of YAP; D: The expression of YAP was mainly in the nucleus in the absence of dobutamine; E: The expression of phosphorylated YAP was mainly in the cytosol after treatment with dobutamine. GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.